Community/Retail

On Wednesday, October 24, and Saturday, October 27, student pharmacists from the University of Maryland School of Pharmacy chapter of the APhA-ASP joined forces with the University of Maryland, Baltimore Police and the Drug Enforcement Administration (DEA) to host our bi-annual Drug Take-Back Day at the University’s SMC Campus Center.

DarioHealth Corp., a leading global digital health company with mobile health and big data solutions, has announced that it has signed an agreement for the rollout of a Digital Diabetes Education and Rewards Program to Giant Eagle's consumers through the pharmacy's 214 locations.

Can you solve the pharmaceutical mystery? Each week, a new case study is presented.

In this clip, Ruth O'Regan, MD discussed the future of chemotherapy as it relates to treating patients with breast cancer.

As targeted therapies for cancer continue to shape the health care landscape, health care providers may increasingly utilize liquid biopsies to identify potential treatment resistance.

The FDA approved Merck’s pembrolizumab (Keytruda) for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.

Site-specific immune inflammation has been examined using intralesional injections of oncolytic viruses.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

The action will increase access to diagnostic tools for healthcare providers who may not have otherwise been equipped to perform tests.

In this clip, Maurie Markman, MD, discusses ovarian cancer as a chronic illness, and an increasing need for precision medicine.

Former New York Giants Running Back Tiki Barber this week delivered the keynote address at the 36th Annual CFS, presented by Physicans' Education Resource, and discussed his mother's breast cancer journey.

In this clip, Jeffrey Lombardo, PharmD, who is the executive patient safety officer for UB’s patient safety organization Empire State Patient Safety Assurance Network, discusses the role of RTU products in pharmacy.

In this clip, Maurie Markman, who spoke at the CFS Symposium in NY this week, discussed the role of pharmacists in managing patients with cancer.

Skin cancer remains the most common form of cancer in the United States, with more than 65,000 cases of melanoma estimated in 2011, according to the CDC.

In this video, Jeffrey Lombardo, PharmD, who is the executive patient safety officer for UB’s patient safety organization Empire State Patient Safety Assurance Network, discusses the use of RTUs in patients with cancer.

In this clip, Jeffrey Lombardo, PharmD, who is the executive patient safety officer for University at Buffalo's patient safety organization Empire State Patient Safety Assurance Network, explains the challenges pharmacists will face in transitioning to USP800.

In this clip, Jeffrey Lombardo, PharmD, who is the executive patient safety officer for University at Buffalo's patient safety organization Empire State Patient Safety Assurance Network, explains the challenges compounding pharmacies will face with USP800.

The product has an estimated market size of $338M for the 12 months ending August 2018 according to IQVIA.

As a first-year student pharmacist, I was initially overwhelmed by the number of student organizations and opportunities to get involved.

Chronic liver disease and cirrhosis can contribute to the development of liver cancer, which affects approximately 33,000 individuals in the United States each year.

Officials with the FDA have approved elotuzumab (Empliciti) injection for intravenous use in combination with pomalidomide and dexamethasone for the treatment of certain patients with relapsed or refractory multiple myeloma.

Medication nonadherence is a major cause of morbidity, especially in elderly patients.

The product has an estimated market size of $338M for the 12 months ending August 2018 according to officials with IQVIA.

The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

Findings showed that LAIV was more effective in those vaccinated in both the enrollment season and the prior season than in those vaccinated only in the enrollment season.

Several large investigations have demonstrated the considerable efficacy of TDF/FTC taken daily or intermittently, reducing the risk of HIV acquisition by more than 95% in high-risk individuals.

This cannabidiol oral solution can be prescribed in the United States to treat seizures associated with Dravet or Lennox-Gastaut syndrome.

The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with ALK-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors.

Although HPV vaccination rates have steadily increased in recent years, more work is needed in this area to effectively reduce HPV-associated cancer, according to a new report release by the President’s Cancer Panel.